Protein-Expression Changes Specific to Immunoglobulin G4-Related Disease Analyzed
By LabMedica International staff writers Posted on 09 Sep 2021 |
Image: Immunohistochemical staining showing IgG4-positive plasma cells (white arrows) from a girl with sclerosing mesenteritis (Photo courtesy of King Saud bin Abdulaziz University for Health Sciences)
Immunoglobulin 4 (IgG4)-related disease (IgG4-RD) is a lymphoproliferative disorder characterized by elevated serum IgG4 levels and infiltration of IgG4-positive plasma cells into the affected tissues.
The pathology of IgG4-related disease cannot be explained based only on the change in a single gene or a protein. Organs affected by this disease are distributed throughout the body, including the lacrimal/salivary glands, pancreas, retroperitoneum, and thyroid. The disease is referred to as Mikulicz disease, autoimmune pancreatitis, retroperitoneal fibrosis, and Riedel thyroiditis, depending on the affected tissues.
A large team of Immunologists and Hematologists at the Kanazawa Medical University (Uchinada-machi, Japan) obtained sera from patients with IgG4-related disease receiving treatments. All patients had serum IgG4 levels ≥135 mg/dL and tissue IgG4/IgG ratios ≥40%, thereby satisfying the diagnostic criteria for IgG4-related disease. The control serum samples were collected from 13 healthy male volunteers (54–64 years old, median age of 59 years old).
Serum proteins from patients with IgG4-related disease and healthy subjects were resolved using two-dimensional electrophoresis, silver-stained, and scanned. Alternatively, the proteins were labeled with Cy2, Cy3, and Cy5 before electrophoresis. The proteins, whose expression differed significantly between patients and healthy individuals, and between before and after steroid treatment, were identified and validated using enzyme-linked immunosorbent assays.
The team used enzyme-linked immunosorbent assay (ELISA) kits for detecting human alpha-1 antitrypsin (A1AT, Immunology Consultants Laboratory, Inc. (Portland, OR, USA), clusterin (BioVender Research and Diagnostic Products, Brno, Czech Republic), and leucine rich α-2-glycoprotein (LRG-1) (Immuno-Biological Laboratories Co., Ltd, Fujioka-Shi, Japan). Pretreatment of the serum samples with ProteoMiner and the serum proteins were processed using a ProteoMiner Small-Capacity Kit (Bio-Rad, Hercules, CA, USA).
The investigators reported that pre-treatment sera from patients with IgG4-related disease was characterized by increased levels of immunoglobulins such as IgG1, IgG4; inflammatory factors such as α-1 antitrypsin (A1AT); and proteins associated with immune system regulation such as clusterin and leucine-rich α-2-glycoprotein (LRG-1). The serum levels of A1AT, LRG-1 and clusterin, during treatment with prednisolone for up to 12 months revealed that LRG-1 levels were halved after one month of treatment, comparable to those in healthy subjects; LRG-1 levels remained normal until the end of treatment.
The authors concluded that A1AT, LRG-1, and clusterin could be involved in the pathogenesis of IgG4-related disease, and their serum levels could reflect the disease state. In particular, LRG-1 could serve as a novel biomarker for the diagnosis and treatment of IgG4-related disease. The study was published on August 25, 2021 in the journal Clinica Chimica Acta.
Related Links:
Kanazawa Medical University
Immunology Consultants Laboratory
BioVender Research and Diagnostic Products
Immuno-Biological Laboratories
Bio-Rad
The pathology of IgG4-related disease cannot be explained based only on the change in a single gene or a protein. Organs affected by this disease are distributed throughout the body, including the lacrimal/salivary glands, pancreas, retroperitoneum, and thyroid. The disease is referred to as Mikulicz disease, autoimmune pancreatitis, retroperitoneal fibrosis, and Riedel thyroiditis, depending on the affected tissues.
A large team of Immunologists and Hematologists at the Kanazawa Medical University (Uchinada-machi, Japan) obtained sera from patients with IgG4-related disease receiving treatments. All patients had serum IgG4 levels ≥135 mg/dL and tissue IgG4/IgG ratios ≥40%, thereby satisfying the diagnostic criteria for IgG4-related disease. The control serum samples were collected from 13 healthy male volunteers (54–64 years old, median age of 59 years old).
Serum proteins from patients with IgG4-related disease and healthy subjects were resolved using two-dimensional electrophoresis, silver-stained, and scanned. Alternatively, the proteins were labeled with Cy2, Cy3, and Cy5 before electrophoresis. The proteins, whose expression differed significantly between patients and healthy individuals, and between before and after steroid treatment, were identified and validated using enzyme-linked immunosorbent assays.
The team used enzyme-linked immunosorbent assay (ELISA) kits for detecting human alpha-1 antitrypsin (A1AT, Immunology Consultants Laboratory, Inc. (Portland, OR, USA), clusterin (BioVender Research and Diagnostic Products, Brno, Czech Republic), and leucine rich α-2-glycoprotein (LRG-1) (Immuno-Biological Laboratories Co., Ltd, Fujioka-Shi, Japan). Pretreatment of the serum samples with ProteoMiner and the serum proteins were processed using a ProteoMiner Small-Capacity Kit (Bio-Rad, Hercules, CA, USA).
The investigators reported that pre-treatment sera from patients with IgG4-related disease was characterized by increased levels of immunoglobulins such as IgG1, IgG4; inflammatory factors such as α-1 antitrypsin (A1AT); and proteins associated with immune system regulation such as clusterin and leucine-rich α-2-glycoprotein (LRG-1). The serum levels of A1AT, LRG-1 and clusterin, during treatment with prednisolone for up to 12 months revealed that LRG-1 levels were halved after one month of treatment, comparable to those in healthy subjects; LRG-1 levels remained normal until the end of treatment.
The authors concluded that A1AT, LRG-1, and clusterin could be involved in the pathogenesis of IgG4-related disease, and their serum levels could reflect the disease state. In particular, LRG-1 could serve as a novel biomarker for the diagnosis and treatment of IgG4-related disease. The study was published on August 25, 2021 in the journal Clinica Chimica Acta.
Related Links:
Kanazawa Medical University
Immunology Consultants Laboratory
BioVender Research and Diagnostic Products
Immuno-Biological Laboratories
Bio-Rad
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms